Pitt Shield

Skeleton keys and Trojan horses: a review of therapeutic delivery to the brain.

Authors: Stoub RE, Bailus BJ

The advances in genetic medicine that have occurred in the last few decades have been tempered by the challenges in delivering those medicines to the desired organs and cell types. Nowhere has this delivery challenge been greater than in the brain, due to the blood brain barrier (BBB), often illustrated as an impenetrable castle wall. As the need for neurological therapies grows, an assortment of Trojan horse and skeleton key strategies have been designed to allow passage of therapeutics through the BBB, These range from designer viral vectors, to cell penetrating peptides that can target cell surface receptors, to genetically modifying hematopoietic stem cells, to lipid nanoparticles that pass through the cell membrane. This review will examine the precise method that each delivery vehicle uses to enter and transverse the endothelial layer of the to BBB and arrive in the brain parenchyma. The advantages and challenges of each delivery strategy will be discussed, as will the most recent clinical trials using these technologies. There are several extremely promising delivery vehicles that are able to cross the BBB and deliver genetic therapies to neuronal cells. Several of these delivery vehicles have already been approved for use in patients. As these delivery vehicles become further optimized there is the potential to treat a majority of neurological disease and disorders.

Introduction

Purpose Drug delivery WITHOUT BBB opening
Study Objective To review and analyze the mechanisms, advantages, challenges, and clinical progress of various delivery strategies for transporting genetic therapies across the blood–brain barrier into the brain.
Animal model / Human subject not provided
Disease model not provided
MRI or image guidance method not provided
Targeted brain region(s) Not Provided
Target coordinates not provided
Cargo name and characteristics Designer viral vectors (e.g., AAV; viral gene therapy vectors), cell-penetrating peptides (peptide/protein-based delivery agents), genetically modified hematopoietic stem cells (cell therapy/genetically engineered cells), lipid nanoparticles (nanoparticles for nucleic acid/drug delivery)
Route of administration intravenous

Outcomes and Safety

Summary of Outcomes Multiple delivery strategies—including designer viral vectors, cell-penetrating peptides, genetically modified hematopoietic stem cells, and lipid nanoparticles—can cross the blood–brain barrier to deliver genetic therapies to neuronal cells, with several platforms already approved and showing promise for treating neurological disorders.
Duration of biological effect not specified
Safety-related matter No explicit safety concerns or adverse effects are reported in the excerpt; it only generically references the "advantages and challenges" of delivery strategies and notes some delivery vehicles are approved for patient use.

Brain Region

Ultrasound Parameters

Ultrasound instrument Not provided
FUS Frequency not provided
FUS Intensity not provided
FUS Pressure not provided
FUS Mode not provided
Pulse duration not provided
Duration of a single FUS session not provided
Focal Characteristics not provided
Treatment frequency not provided

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search